DCR-PDL1 for Cancer

Recruiting at 1 trial location

Overseen By Novo Nordisk

Age: 18+

Sex: Any

Trial Phase: Phase 1

Sponsor: Dicerna Pharmaceuticals, Inc., a Novo Nordisk company

Disqualifiers: CNS metastases, others

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Compensation: Varies

Number of Visits: Unknown

Duration: 8 weeks

32 Participants Needed

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial tests a new treatment called DCR-PDL1 to assess its safety and behavior in the body. It targets adults with solid tumors or non-Hodgkin's lymphoma that have not responded to standard treatments or for whom no standard treatments exist. Participants will receive the medication through a series of IV doses, with each group trying a different dose level to determine the safest and most effective amount. This trial may suit those whose cancer has worsened despite treatment or cannot be treated with surgery. As a Phase 1 trial, the research aims to understand how the treatment works in people, offering participants the opportunity to be among the first to receive this new treatment.

Will I have to stop taking my current medications?

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

Is there any evidence suggesting that DCR-PDL1 is likely to be safe for humans?

Research shows that treatments targeting PD-L1, such as DCR-PDL1, are usually well-tolerated. Studies with similar PD-1 and PD-L1 inhibitors have reported few side effects, with serious side effects being rare. While these treatments are mostly safe, some patients might still experience mild side effects, including tiredness, skin reactions, or flu-like symptoms. When used for other conditions, these treatments generally support their safety for new uses. Always consult a doctor about specific risks and benefits before joining a trial. ^{1 2 3 4 5}

Why do researchers think this study treatment might be promising?

Most treatments for cancer focus on targeting tumor cells directly or boosting the immune system to attack them. DCR-PDL1 is unique because it uses an innovative mechanism to silence the PD-L1 protein, which often helps cancer cells evade the immune system. By targeting PD-L1, this treatment could potentially enhance the body's natural ability to fight cancer more effectively than existing immunotherapies. Researchers are excited about DCR-PDL1 because this approach might offer a new way to overcome resistance seen with current therapies, potentially leading to better outcomes for patients.

What evidence suggests that DCR-PDL1 might be an effective treatment for cancer?

Research has shown that PD-1 and PD-L1 inhibitors hold promise in cancer treatment. These treatments can extend the time patients live without their cancer worsening. For instance, patients using similar PD-1 inhibitors lived about 11.5 months without cancer progression, compared to just 2.9 months for those not using these inhibitors. Additionally, about 23-28% of patients experienced a partial or full reduction in tumor size with these treatments. This trial will evaluate DCR-PDL1, which functions similarly, to assess its potential effectiveness in treating solid tumors. ^{1 2 6 7 8}

Who Is on the Research Team?

Clinical Transparency (dept. 2834)

Principal Investigator

Novo Nordisk A/S

Are You a Good Fit for This Trial?

This trial is for adults with solid tumors. Participants will be placed into one of four groups to receive increasing doses of DCR-PDL1, given through the veins. Specific eligibility details are not provided, but typically include factors like type and stage of tumor, previous treatments, and overall health.

Inclusion Criteria

My cancer is advanced, not responding to standard treatments, or there are no treatments available.

Measurable disease according to RECIST version 1.1

Other protocol defined inclusion criteria could apply

Exclusion Criteria

Other protocol defined exclusion criteria could apply

I have brain or spinal cord metastases not managed by surgery or radiation.

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive multiple IV doses of DCR-PDL1 during each treatment cycle in one of 4 ascending-dose cohorts

8 weeks

Multiple visits for IV dosing

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

What Are the Treatments Tested in This Trial?

Interventions

• DCR-PDL1

Trial Overview

The study tests the safety and how well the body handles DCR-PDL1 when administered intravenously in adults with solid tumors. It involves multiple IV doses within treatment cycles, with close monitoring to decide if higher doses can be safely given.

How Is the Trial Designed?

Group I: DCR-PDL1 Experimental Treatment 1 Intervention

Participants will receive multiple IV doses of DCR-PDL1 during each treatment cycle.

Who Is Running the Clinical Trial?

Dicerna Pharmaceuticals, Inc., a Novo Nordisk company

Lead Sponsor

Trials

19

Recruited

580+

Published Research Related to This Trial

In a systematic review of 125 clinical trials involving over 20,000 patients, 66% experienced at least one treatment-related adverse event from PD-1 and PD-L1 inhibitors, with fatigue, pruritus, and diarrhea being the most common.

Nivolumab was found to have a higher incidence of adverse events compared to pembrolizumab, and PD-1 inhibitors generally led to more severe adverse events than PD-L1 inhibitors, highlighting the importance of understanding these differences for clinical decision-making.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials: A Systematic Review and Meta-analysis. Wang, Y., Zhou, S., Yang, F., et al.[2022]

Genetically modifying T cells to express a PD1-CD28-4-1BB receptor (PD1-ACR) enhances their ability to overcome PDL1-mediated immunosuppression, leading to improved T cell activation and function.

In a mouse model of glioblastoma, PD1-ACR T cells effectively localized to tumors, suppressed tumor growth, and improved survival rates, suggesting a promising new approach for cancer therapy.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

The advantages of PD1 activating chimeric receptor (PD1-ACR) engineered lymphocytes for PDL1(+) cancer therapy. Tang, X., Li, Q., Zhu, Y., et al.[2020]

In a study of 158 advanced biliary tract cancer patients, higher levels of soluble PD-L1 (sPDL1) in serum were associated with significantly worse overall survival, indicating its potential as a prognostic biomarker.

Patients with sPDL1 levels of 0.94 ng/mL or higher had a median overall survival of 7.93 months compared to 14.10 months for those with lower levels, highlighting sPDL1 as an independent poor prognostic factor alongside the neutrophil-to-lymphocyte ratio.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Soluble programmed death-ligand 1 (sPDL1) and neutrophil-to-lymphocyte ratio (NLR) predicts survival in advanced biliary tract cancer patients treated with palliative chemotherapy. Ha, H., Nam, AR., Bang, JH., et al.[2022]

This study aims to create a comprehensive toxicity profile for anti-PD-1 and anti-PD-L1 drugs by analyzing systematic reviews and meta-analyses, focusing on treatment-related adverse events in cancer patients.

The research will utilize a network meta-analysis approach to synthesize data from various studies, ensuring a thorough understanding of the safety and adverse effects associated with these immunotherapy treatments.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Anti-PD-1 and anti-PD-L1 drugs treatment-related adverse events for patients with cancer: Protocol for an overview of systematic reviews with meta-analyses. Li, J., Liu, M., Wang, J., et al.[2023]

In a study of 191 patients with non-small cell lung cancer (NSCLC) treated with PD-1/PD-L1 inhibitors, those who experienced immune-related adverse events (irAEs) had significantly better treatment outcomes, with an objective response rate of 42.0% compared to 25.8% in those without irAEs.

The presence of irAEs was associated with improved progression-free survival, suggesting that these adverse events may indicate a more effective immune response to the treatment, although they did not correlate with overall survival.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Immune-Related Adverse Events and Their Association With the Effectiveness of PD-1/PD-L1 Inhibitors in Non-Small Cell Lung Cancer: A Real-World Study From China. Chen, X., Nie, J., Dai, L., et al.[2022]

Immune checkpoint antibodies targeting the PD-1/PD-L1 pathway have shown significant antitumor activity and have been approved for use as single-agent therapies in metastatic malignant melanoma and nonsmall-cell lung cancer.

Understanding the toxicities associated with PD-1/PD-L1 blockade and having effective management strategies is crucial for maximizing both the safety and efficacy of these treatments.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. Naidoo, J., Page, DB., Li, BT., et al.[2023]

In a study of 128 cancer patients undergoing immune checkpoint inhibitor therapy, high levels of circulating soluble programmed death-1 ligand (sPD-L1) were linked to a higher likelihood of disease progression (41.8% vs. 20.7% for low levels), indicating its potential as a prognostic marker.

Patients with elevated sPD-L1 levels had significantly shorter progression-free survival (PFS) and overall survival (OS), with median PFS of 2.9 months compared to 6.3 months and median OS of 7.4 months compared to 13.3 months for those with low levels, suggesting that sPD-L1 could help predict treatment outcomes.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Soluble PD-L1 is a predictive and prognostic biomarker in advanced cancer patients who receive immune checkpoint blockade treatment. Oh, SY., Kim, S., Keam, B., et al.[2021]

In a study of 62 lung cancer specimens, 71% showed positive expression of PDL-1, with significantly higher levels in non-small cell lung cancer (NSCLC) compared to small cell lung cancer (SCLC), suggesting PDL-1's role in tumor immune evasion.

The study indicates that while PDL-1 is overexpressed in lung cancer and correlates with EGFR overexpression, patients with positive PDL-1 expression had lower overall and progression-free survival, highlighting the need for alternative treatment strategies for PDL-1-negative tumors.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

PDL-1 expression in lung carcinoma and its correlation with clinicopathological and prognostic characteristics. Farrag, M., Ibrahim, E., Abdelwahab, H., et al.[2022]

In a study of 150 renal cell carcinoma (RCC) patients, 44% showed positive expression of the PD-L1 protein, which is linked to the tumor's ability to evade the immune response.

There was a significant association between high tumor grades and positive PD-L1 expression, suggesting that targeting the PD-1/PD-L1 pathway could be a promising immunotherapy strategy for aggressive RCC cases.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Programmed Death Ligand 1; An Immunotarget for Renal Cell Carcinoma. Chandrasekaran, D., Sundaram, S., N, K., et al.[2020]

The overall incidence of anaemia in patients receiving PD-(L)1 inhibitors was found to be 9.8%, with a higher occurrence in certain cancer types and phase II studies, indicating a notable risk that clinicians should monitor.

Severe cases of neutropenia and thrombocytopenia were rare, with incidences of 1.07% and 1.8% respectively, suggesting that while anaemia is a concern, other serious blood-related toxicities are less common with PD-(L)1 therapy.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Haematological toxicities with immunotherapy in patients with cancer: a systematic review and meta-analysis. Petrelli, F., Ardito, R., Borgonovo, K., et al.[2019]

The study found that MACC1, c-Met, and PDL1 are all upregulated in gastric cancer tissues, indicating a positive correlation that may contribute to immune evasion in tumors.

Silencing MACC1 enhances antitumor immunity, while its overexpression reduces tumor immunity, suggesting that targeting MACC1 could be a promising strategy for improving immunotherapy in gastric cancer.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

MACC1 regulates PDL1 expression and tumor immunity through the c-Met/AKT/mTOR pathway in gastric cancer cells. Tong, G., Cheng, B., Li, J., et al.[2021]

In a study of 158 patients with metastatic non-small cell lung cancer (mNSCLC) receiving chemotherapy, those with low levels of programmed cell death protein-1 ligand (PDL-1) experienced longer progression-free survival (PFS) compared to those with high PDL-1 levels, indicating that PDL-1 levels may influence treatment outcomes.

The research also found a significant correlation between PDL-1 levels and the neutrophil-to-lymphocyte ratio (NLR), suggesting that patients with low PDL-1 and low NLR may benefit from immunogenic chemotherapies like gemcitabine and taxane as alternative treatment options.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

PDL-1 Expression and Survival in Metastatic Non-small Cell Lung Cancer Patients Who Received Chemotherapy as First-Line Treatment. Gursoy, P., Çakar, B., Gunenc, D., et al.[2022]

In a study of 899 lymphoma cases, PDL1 was found to be expressed in a significant portion of classical Hodgkin lymphoma (70%) and primary mediastinal B-cell lymphomas (35%), indicating its potential role in tumor immune evasion.

The expression of PDL1 in classical Hodgkin lymphoma correlated with increased immune cell activity, such as granzyme+ T cells and CD68+ macrophages, suggesting that PDL1 may serve as a marker for immune response and could help identify patients who might benefit from PD1/PDL1-targeted therapies.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Evaluation of the diagnostic and prognostic value of PDL1 expression in Hodgkin and B-cell lymphomas. Menter, T., Bodmer-Haecki, A., Dirnhofer, S., et al.[2022]

Citations

1.

pmc.ncbi.nlm.nih.gov

pmc.ncbi.nlm.nih.gov/articles/PMC5601788/

Effectiveness and safety of PD-1/PD-L1 inhibitors in the ...

In one of the trials [31], the median PFS of patients treated with PD-1 inhibitor was 11.5 months, while it was only 2.9 months for those treated without PD-1 ...

2.

clinicaltrials.gov

clinicaltrials.gov/study/NCT06504368

Safety, Tolerability, and Pharmacokinetics of DCR-PDL1 in ...

Study Details | NCT06504368 | Safety, Tolerability, and Pharmacokinetics of DCR-PDL1 in Adults With Solid Tumors | ClinicalTrials.gov.

3.

frontiersin.org

frontiersin.org/journals/immunology/articles/10.3389/fimmu.2025.1430673/full

Effectiveness and safety of PD-1/L1 inhibitors as first-line ...

Our results revealed that PD-1/L1 inhibitors had certain therapeutic advantage, with ORR of 28% and DCR of 57%. Besides, the median PFS and OS ...

4.

pmc.ncbi.nlm.nih.gov

pmc.ncbi.nlm.nih.gov/articles/PMC11368785/

Efficacy of PD-1 or PD-L1 inhibitors for the therapy of cervical ...

For patients exhibiting PD-L1 positivity, median PFS and median OS were 3.98 months (95% CI: 0.80–7.16, P = 0.01) and 11.26 months (95% CI: 3.01 ...

5.

bmcgastroenterol.biomedcentral.com

bmcgastroenterol.biomedcentral.com/articles/10.1186/s12876-022-02511-7

Efficacy and safety of anti-PD-1/PD-L1 therapy in the treatment ...

The objective response rate (ORR) of anti-PD-1/PD-L1 was 23% (95% CI 0.14, 0.31); the overall 1-year survival rate (OSR) was 57% (95% CI 0.42, ...

6.

aacrjournals.org

aacrjournals.org/clincancerres/article/27/5/1267/83962/Safety-and-Clinical-Activity-of-a-New-Anti-PD-L1

Safety and Clinical Activity of a New Anti-PD-L1 Antibody as ...

Clinical efficacy and antitumor activity endpoints included objective response rate (ORR), duration of response (DoR), disease control rate (DCR), PFS, and OS.

7.

bmccancer.biomedcentral.com

bmccancer.biomedcentral.com/articles/10.1186/s12885-024-11833-6

Efficacy and safety of anti-PD-1 inhibitor versus ... - BMC Cancer

Anti-PD-1 agents and anti-PD-L1 agents combined with chemotherapy as first-line treatment for ES-SCLC are comparably effective and well tolerated.

8.

frontiersin.org

frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1485303/full

Efficacy and safety of PD-1/PD-L1 and CTLA-4 immune ...

A recent study showed that 100% of 12 patients with advanced dMMR rectal cancer achieved a complete clinical and pathological response after six months of ...